Terry Vance - 13 Dec 2023 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: Director
Signature: /s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol: ENTA
Transactions as of: 13 Dec 2023
Net transactions value: -$139,490
Form type: 4
Filing time: 15 Dec 2023, 20:08:21 UTC
Previous filing: 17 Mar 2023
Next filing: 08 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Sale	$139,490	-15,295	-73%	$9.12	5,800	13 Dec 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.56, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Content

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.56, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.